EDCTP

8:30-8:55 

Plenary session V: Capacity development in sub-Saharan Africa
Chair             Prof. Tumani Corrah

Plenary session: Dr Michael Makanga
Challenges of capacity development in sub-Saharan Africa: EDCTP strategy (20 minutes talk, 5 minutes questions)

8:55-9:00      Transfer to parallel sessions

9:00-10:20
Parallel sessions: Clinical Trials research findings in sub-Saharan Africa and Scientific Presentations by EDCTP Fellows

HIV/AIDS  
Chairs             Prof. Nkandu P. Luo and Dr Abraham Alabi
9:00-9:05         Brief introduction from the Chairs
9:05-9:20         Bahati Andrew & Justine Bukenya: Prevalence of intra-vaginal practices in EDCTP cohorts in Uganda and 
                       Tanzania & Sexual risk behaviour and risk perception among female sex workers enrolled in a microbicide 
                       feasibility study in Kampala, Uganda
9:20-9:35         Papa Gallo Sow: Perceptions and practices regarding microbicides. A baseline survey of the social health 
                       institute of Dakar
9:35-9:50         Suzan Nakate: Barriers to adherence to clinical appointments in a free Urban HIV care facility. A case of the 
                       Infectious Diseases Institute Kampala, Uganda
9:50-10:05       Jean Nachega: The effect of pregnancy on adherence to highly active antiretroviral therapy among HIV-
                       infected South African women: A pharmacy claims-based analysis
10:05-10:20     Mariam A Adetunji: Risk of coronary heart disease based on ratio of total cholesterol to high density 
                       lipoprotein in HIV infected ARV naïve patients

Malaria      
Chairs              Dr Andrew Kitua and Dr Klaus Winkel
9:00-9:05          Brief introduction from the Chairs
9:05-9:20          Davis Nwakanma: Application of real-time quantitative polymerase chain reaction 'opcr' in anti-malarial drug 
                         trial
9:20-9:35          Alexis Nzila: In-vitro chemosensitization of antimalarials by verapamil and probenecid in Plasmodium 
                        falciparum
9:35-9:50          Leah Mwai: Towards understanding the mechanisms of lumefantrine resistance.
9:50-10:05        Takafira Muduluza: Cytokine gene polymorphism analysis in children exposed to malaria and/or helminths 
                        infections in Zimbabwe
10:05-10:20      Ayola Akim Adegnika: Ascaris lubriciodes as a risk factor for P. falciparum malaria infection during 
                        pregnancy in Lambaréné, Gabon

Tuberculosis 
Chairs               Dr Veronique N. Penlap and Prof. Martin Grobusch
9:00-9:05           Brief introduction from the Chairs
9:05-9:20           Gibson Kibiki: New drugs against tuberculosis: Problems, progress, and evaluation of agents in clinical 
                         development
9:20-9:35           Yusuf Mohammed: Response to treatment in sputum smear positive pulmonary tuberculosis patients in 
                         relation to human immunodeficiency virus in Kano, Nigeria.
9:35-9:50           Sven Friedrich: Comparison of smear microscopy, solid culture and liquid culture for monitoring treatment 
                         response in pulmonary tuberculosis
9:50-10:05         Bernd Eisele: Induction of antigen specific multifunctional T cells after vaccination with the live recombinant 
                         tuberculosis vaccine VPM1002 in a Phase I clinical trial
10:05-10:20       Jan Verschoor: Mycolic acid antibody real-time inhibition test demonstrates that anti-mycolic acid antibodies 
                         are surrogate markers for active tuberculosis

10:20-10:50     Coffee/Tea Break

10:50-12:00 

Parallel sessions: Clinical Trials research findings in sub-Saharan Africa and Scientific Presentations by EDCTP Fellows continues

HIV/AIDS  
Chairs              Prof. Nkandu P. Luo and Dr Abraham Alabi
10:50-11:05       Louis-Marie Yindom: Hla alleles and kir genes frequencies in HIV-2 infected individuals from two cohorts in 
                         West Africa
11:05-11:20       Mattia Prosperi: Prediction of antiretroviral therapy outcomes in poor resource countries: Comparison 
                         between genotype resistance testing based versus treatment history models
11:20-11:35       Sabina Mugusi: The effect of rifampicin on clinical outcomes in patients treated with efavirenz containing 
                         HAART.
11:35-11:50       Joseph Vyankandondera: Prevalence of HPV and association with other STIs among High-Risk women in 
                         Kigali, Rwanda
11:50-12:00       Discussion

Malaria      
Chairs               Dr Andrew Kitua and Dr Klaus Winkel
10:50-11:05        Daniel Dodoo: The Afro-immuno assay multi-centre network project and capacity building for malaria
                          vaccine development in Africa
11:05-11:20        Aïssatou Toure: The ADRB assay: a new tool, correlated with clinical protection from Plasmodium
                          falciparum malaria, to test malaria vaccine
11:20-11:35        Charles Arama: Decreased percentage of plasmacytoid dendritic cells and increased plasma levels of 
                          interferon alpha in Fulani children undergoing Plasmodium falciparum infection in Mali.
11:35-11:50        Victor Chalwe: HIV-1 infection increases the risk of severe malaria in semi-immune adults in Zambia
11:50-12:00        Discussion

Tuberculosis 
Chairs                Dr Veronique N. Penlap and Prof. Martin Grobusch
10:50-11:05         Hulda Swai: Novel approach to address the tuberculosis treatment regime
11:05-11:20         Agatha Ani: Dominant Mycobacterium tuberculosis genotypes in Nigeria
11:20-11:35         Sayoki G Mfinanga: Estimates of genetic variability of M. tuberculosis complex and its association with drug 
                           resistance and treatment outcomes in Tanzania.
11:35-11:50         Kebba Touray: Spatial analysis of tuberculosis in an urban West African setting: Is there evidence of 
                           clustering?
11:50-12:00         Discussion

12:00-13:00       Electronic and paper poster presentations

13:00-14:00       Lunch

14:00-15:35
Plenary session VI: EDCTP and Global Partnerships
Chairs:              Dr Michael Makanga/Dr Dirk van der Roost

14:00-14:05        Brief introduction from the Chairs
14:05-14:15        The AAVP and UVRI model: Building research capacity through partnerships in synergy with 
                          EDCTP
14:15-14:25        IPM: International Partnership for Microbicides
14:25-14:35        Wellcome Trust
14:35-14:45        Bill and Melinda Gates Foundation
14:45-14:55        ESSENCE: Enhancing Support for Strengthening the Effectiveness of National Capacity Effort
14:55-15:05        AMANET: African Malaria Network Trust
15:05-15:15        EMVI: European Malaria Vaccine Initiative
15:15-15:25        MMV: Medicines for Malaria Venture
15:25-15:35        Aeras Global TB Vaccine Foundation

15:35-16:00      Tea/Coffee break

16:00-17:30 

Closing plenary session VII: EDCTP future perspectives

Chairs:              Prof. David Ofori-Adjei and Dr Christian Burri

16:00-16:45:       Dr Sodiomon Sirima / Prof. Charles Mgone–EDCTP: one world, one partnership
                          Forum recommendations and EDCTP–future research direction including new developments such a health 
                          services research.
16:45-17:00:       Award giving ceremony for outstanding African scientists
17:00-17:15:       Dr Ruxandra Draghia-Akli, The Director of Health, European Commission           

Future EDCTP perspective from the European Commission and Concluding Remarks

 

19:00-20.30        Closing dinner and award giving ceremony for young future scientists: 
                          Essay competition winners